Cargando…
Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder
BACKGROUND: In Major Depressive Disorder (MDD), treatment outcomes with currently available strategies are often disappointing. Therefore, it is sensible to develop new strategies to increase remission rates in acutely depressed patients. Many studies reported that true drug response can be observed...
Autores principales: | Tadić, André, Wagner, Stefanie, Gorbulev, Stanislav, Dahmen, Norbert, Hiemke, Christoph, Braus, Dieter F, Lieb, Klaus |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037852/ https://www.ncbi.nlm.nih.gov/pubmed/21269443 http://dx.doi.org/10.1186/1471-244X-11-16 |
Ejemplares similares
-
Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder - the EMC trial
por: Tadić, André, et al.
Publicado: (2010) -
Early improvement of executive test performance during antidepressant treatment predicts treatment outcome in patients with Major Depressive Disorder
por: Wagner, Stefanie, et al.
Publicado: (2018) -
Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder
por: Dreimüller, Nadine, et al.
Publicado: (2019) -
Association analysis between variants of the interleukin-1β and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression
por: Tadić, André, et al.
Publicado: (2008) -
Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial
por: Engelmann, J., et al.
Publicado: (2022)